• Special Issue Topic

    Biomarkers for Personalized and Precise Cancer Diagnosis and Treatment

    Submission Deadline: January 20, 2023

    Guest Editor

    Dr. Arun Seth E-Mail

    Scientific Director of Molecular Diagnostics, Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre; Academic Director, Genomics Core Facility, Senior Scientist, Sunnybrook Research Institute; Professor, Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, Canada

    Research Keywords: precision oncology; breast and prostate cancer biology; molecular diagnostics; genomic profiling; next-generation sequencing; targeted cancer therapy

    About the Special Issue

    Biomarkers are biological molecules that can be evaluated as an indicator of a normal biological and pathogenic process, or a pharmacologic response to a drug. Identification of key cancer biomarkers is crucial for diagnosis, prognosis, treatment, and therapeutic responses. A wide range of technologies have been used to study and discover biomarkers including mass spectrometry, imaging, next generation sequencing.
    Cancer is a complex disease and develops due to the accumulation of genetic and epigenetic alterations. Precision cancer medicine promotes treatment options based on a patient's profile of genetic variations. This requires validated predictive and prognostic biomarkers that can guide the clinical management of individual cancer patients. The focus in precision and personalized cancer medicine is to identify effective approaches for patients based on genetic factors. Most tumors harbor genetic mutations unique to each patient’s cancer. A subset of these mutations drive oncogenesis by conferring a selective growth advantage to the tumor cell. Many cancers specific changes are druggable with highly specific anticancer agents such as small molecules or monoclonal antibodies. In certain cancer cases, companion diagnostic tests are used to identify safe and effective use of a corresponding targeted therapeutic. Precisely targeted mutated proteins can specifically inhibit cancerous cell growth and achieve remission with fewer side effects than traditional chemotherapies.

    Keywords: Biomarkers; precision oncology; molecular diagnostics; companion diagnostics; patient profiling; personalized medicine; targeted therapy; genomics; transcriptomics; proteomics; metabolomics; imaging

    Call for Papers

    Published Articles

    Open Access
    Biomarkers in renal cell carcinoma and their targeted therapies: a review
    Renal cell carcinoma (RCC) is one of the most life-threatening urinary malignancies displaying poor response to radiotherapy and chemotherapy. Although in the recent past there have been tremendous  [...] Read more.
    Shruti Gupta, Shamsher Singh Kanwar
    Published: October 25, 2023 Explor Target Antitumor Ther. 2023;4:941–961
    DOI: https://doi.org/10.37349/etat.2023.00175
    Times Cited: 0
    Open Access
    Original Article
    Exploring the implications of modified advanced lung cancer inflammation index on outcomes in patients with advanced non-small cell lung cancer
    Aim: Sarcopenia and skeletal muscle density (SMD) have been shown to be both predictive and prognostic marker in oncology. Advanced lung cancer inflammation index (ALI) has been shown to predict  [...] Read more.
    Abhishek Mahajan ... Kumar Prabhash
    Published: October 11, 2023 Explor Target Antitumor Ther. 2023;4:896–911
    DOI: https://doi.org/10.37349/etat.2023.00172
    Times Cited: 0
    Open Access
    AGEs and RAGE: metabolic and molecular signatures of the glycation-inflammation axis in malignant or metastatic cancers
    From attributing mutations to cancers with the advent of cutting-edge genetic technology in recent decades, to re-searching the age-old theory of intrinsic metabolic shift of cancers (Warburg’s gl [...] Read more.
    Gowri Palanissami, Solomon F.D. Paul
    Published: September 28, 2023 Explor Target Antitumor Ther. 2023;4:812–849
    DOI: https://doi.org/10.37349/etat.2023.00170
    Times Cited: 0
    Open Access
    Malignant tumors of the external auditory canal: diagnosis, treatment, genetic landscape, biomarkers, and clinical outcome
    Malignant tumors of the external auditory canal (EAC) are rare neoplasms that appear in the head and neck area. A common feature of these malignancies is their rarity, as well as their delayed diagn [...] Read more.
    Pinelopi Samara ... Ioannis Athanasopoulos
    Published: September 21, 2023 Explor Target Antitumor Ther. 2023;4:801–811
    DOI: https://doi.org/10.37349/etat.2023.00169
    Open Access
    Original Article
    Deep learning based automated epidermal growth factor receptor and anaplastic lymphoma kinase status prediction of brain metastasis in non-small cell lung cancer
    Aim: The aim of this study was to investigate the feasibility of developing a deep learning (DL) algorithm for classifying brain metastases from non-small cell lung cancer (NSCLC) into epidermal  [...] Read more.
    Abhishek Mahajan ... Kumar Prabhash
    Published: August 30, 2023 Explor Target Antitumor Ther. 2023;4:657–668
    DOI: https://doi.org/10.37349/etat.2023.00158
    Open Access
    Original Article
    Deep learning based clinico-radiological model for paediatric brain tumor detection and subtype prediction
    Aim: Early diagnosis of paediatric brain tumors significantly improves the outcome. The aim is to study magnetic resonance imaging (MRI) features of paediatric brain tumors and to develop an auto [...] Read more.
    Abhishek Mahajan ... Aliasgar Moiyadi
    Published: August 30, 2023 Explor Target Antitumor Ther. 2023;4:669–684
    DOI: https://doi.org/10.37349/etat.2023.00159
    Open Access
    Capitalizing glycomic changes for improved biomarker-based cancer diagnostics
    Cancer serum biomarkers are valuable or even indispensable for cancer diagnostics and/or monitoring and, currently, many cancer serum markers are routinely used in the clinic. Most of those markers  [...] Read more.
    Maria Luísa S. Silva
    Published: June 28, 2023 Explor Target Antitumor Ther. 2023;4:366–395
    DOI: https://doi.org/10.37349/etat.2023.00140
    Open Access
    Case Report
    Complete response to third-line treatment with trifluridine/tipiracil (TAS-102) in stage IV colon adenocarcinoma
    A clinical case of a 61-year-old female diagnosed with stage IV right colon adenocarcinoma (unresectable liver and multiple lymph node metastases at the time of diagnosis), Kirsten rat sarcoma viral [...] Read more.
    Celia Lara-Morga ... Luis Cabezón-Gutiérrez
    Published: April 27, 2023 Explor Target Antitumor Ther. 2023;4:307–315
    DOI: https://doi.org/10.37349/etat.2023.00136
    Times Cited: 0